Otsuka Pharmaceutical Development & Commercialization
Trial Pipeline
A Trial to Assess How Centanafadine Interacts With Stimulants in the Body
NCT07314333
A Study to Evaluate the Safety and Efficacy of JNT-517 in Participants With Phenylketonuria (PKU)
NCT06971731
A Phase 2 Study of JNT-517 in Adolescent Participants With Phenylketonuria
NCT06637514
P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety
NCT06973577
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
NCT06894212
Trial of the Impact of Sibeprenlimab on Immunoglobulin A Nephropathy Kidney Tissue
NCT06740526
A Study to See Iftolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old withAutosomal Recessive Polycystic Kidney Disease (ARPKD)
NCT04782258
A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren's
NCT06928142
First-in-Human, Multiple Part Clinical Study of JNT-517 in Healthy Participants and in Participants With Phenylketonuria
NCT05781399
Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)
NCT05248646
A Trial of Centanafadine Long-term Safety in Children and Adolescents With Attention-deficit/Hyperactivity Disorder.
NCT05279313
A Trial to Test the Effects of Other Drugs on SEP-380135 in Healthy Men and Women
NCT07305779
A Clinical Study to Learn if SEP-363856 Has Physical Dependence in Adults With Schizophrenia
NCT05848700
Trial to Demonstrate the Equivalence of Two Different Strengths of Oral Centanafadine Capsules in Healthy Subjects
NCT07486895
A Clinical Study That Will Assess How Food Moves Through the Stomach and Effects Blood Glucose Levels in Subjects With Schizophrenia Taking SEP-363856 or and Prior Antipsychotic (PA) Standard
NCT05402111
A Clinical Trial Study to Determine the Effect of an Investigational Drug (SEP-363856) Has on the Way That the Drug Metformin Travels Through the Body in People With Schizophrenia.
NCT04865835
Evaluating the Safety and Tolerability of Brexpiprazole in the Treatment of Adults With Borderline Personality Disorder (BPD)
NCT04186403
A 12-week Extension Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type
NCT03594123
A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder
NCT03538691
A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes, Associated With Bipolar I Disorder
NCT03257865
A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes Associated With Bipolar I Disorder
NCT03259555
Study to Determine the Pharmacokinetics, Safety & Tolerability of Aripiprazole in Adults With Schizophrenia
NCT03150771
Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral Brexpiprazole (OPC- 34712) in Adolescents With Schizophrenia
NCT02411695
Study of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious Distress
NCT02196506
Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo
NCT02192554
Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type
NCT01922258
A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole in the Treatment of Alzheimer's Agitation
NCT01862640
A Safety Study to Evaluate the Use and Effectiveness of a Topical Ointment to Treat Adults With Atopic Dermatitis
NCT01702181
Efficacy Study of OPC-34712 in Adults With Acute Schizophrenia
NCT01393613
Study of the Effectiveness of Three Different Doses of OPC-34712 in the Treatment of Adults With Acute Schizophrenia
NCT01396421
Trial to Evaluate the Effects of OPC-34712 on QT/QTc in Subjects With Schizophrenia or Schizoaffective Disorder
NCT01423916
Observational Study in Patients With Autosomal Dominant Polycystic Kidney Disease
NCT01430494
Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKD
NCT01210560
IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients
NCT01009840
Study of the Safety and Efficacy of OPC-34712 as a Complementary Therapy in the Treatment of Adult Attention Deficit/Hyperactivity Disorder
NCT01074294
Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder
NCT01052077
PK-directed Dose Adjustment of IV Busulfan Conditioning Regimen for Autologous Stem Cell Transplant in Lymphoma Patients
NCT00948090
Multicenter, Open-label, Safety and Tolerability Study
NCT01649557
Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
NCT00731549
Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
NCT00705783
Aripiprazole and Effexor XR Drug Interaction Study
NCT00362271
Drug-drug Interaction Study of Aripiprazole and Lamotrigine in Patients With Bipolar Type I Disorder
NCT00321516
A Phase IV Study of the Safety and Efficacy of Aripiprazole in Combination With Lamotrigine in the Long-Term Maintenance Treatment of Patients With Bipolar I Disorder With A Recent Manic or Mixed Episode
NCT00277212
A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania
NCT00261443
A Study of Aripiprazole in Patients With Major Depressive Disorder
NCT00105196
Heart Pressure Assessment Study With Tolvaptan to Treat Congestive Heart Failure
NCT00132886
A Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depressive Episode
NCT00094432
Aripiprazole Oral Acceptability Trial
NCT00101569
Intramuscular Aripiprazole in Acutely Agitated Patients Diagnosed With Dementia
NCT00095719
Aripiprazole in Patients With Psychosis Associated With Parkinson's Disease
NCT00095810
Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's Type
NCT00041678
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 13 |
| Phase 2 | 11 |
| Phase 3 | 50 |
| Phase 4 | 3 |
Therapeutic Areas
What the Pipeline for Otsuka Pharmaceutical Development & Commercialization Shows
According to the ClinicalTrials.gov registry, Otsuka Pharmaceutical Development & Commercialization is linked to 79 US clinical trials across every stage of research activity. Of those, 35 studies are currently recruiting — about 44% of the sponsor's indexed portfolio — and 40 are already marked complete, representing roughly 51% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Otsuka Pharmaceutical Development & Commercialization reports 53 late-stage studies (Phase 3 and Phase 4 combined) and 24 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Otsuka Pharmaceutical Development & Commercialization is Schizophrenia with 12 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.